{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T01:28:24Z","timestamp":1778376504804,"version":"3.51.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2018,12,15]]},"DOI":"10.1007\/s11154-018-9463-2","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T01:14:49Z","timestamp":1537492489000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Thyroid disorders induced by checkpoint inhibitors"],"prefix":"10.1007","volume":"19","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Citi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Benvenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"9463_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116\u201329.","journal-title":"Eur J Cancer"},{"key":"9463_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109\u201317.","journal-title":"Lancet"},{"key":"9463_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u201330.","journal-title":"J Clin Oncol"},{"key":"9463_CR4","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138.","journal-title":"J Clin Oncol"},{"key":"9463_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1677\/ERC-08-0337","volume":"16","author":"A Antonelli","year":"2009","unstructured":"Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer. 2009;16:1299\u2013311.","journal-title":"Endocr Relat Cancer"},{"key":"9463_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.cyto.2012.04.042","volume":"59","author":"A Antonelli","year":"2012","unstructured":"Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, et al. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine. 2012;59:218\u201322.","journal-title":"Cytokine"},{"key":"9463_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.cyto.2011.04.022","volume":"55","author":"A Antonelli","year":"2011","unstructured":"Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine. 2011;55:288\u201393.","journal-title":"Cytokine"},{"key":"9463_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14737140.2018.1417845","volume":"18","author":"A Antonelli","year":"2018","unstructured":"Antonelli A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid cancer. Expert Rev Anticancer Ther. 2018;18:149\u201359.","journal-title":"Expert Rev Anticancer Ther"},{"key":"9463_CR9","unstructured":"https:\/\/www.drugs.com\/history\/yervoy.html [Accessed June 2018]."},{"key":"9463_CR10","unstructured":"https:\/\/www.drugs.com\/history\/keytruda.html [Accessed June 2018]."},{"key":"9463_CR11","doi-asserted-by":"publisher","unstructured":"Hansen ED, Wang X, Case AA, Puzanov I, Smith T. Immune checkpoint inhibitor toxicity review for the palliative care clinician. J Pain Symptom Manage. 2018 May 21. https:\/\/doi.org\/10.1016\/j.jpainsymman.2018.05.015. [Epub ahead of print], Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician.","DOI":"10.1016\/j.jpainsymman.2018.05.015"},{"key":"9463_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1479-5876-12-141","volume":"12","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Marincola FM. What have we learned from cancer immunotherapy in the last 3 years? J Transl Med. 2014;12:141.","journal-title":"J Transl Med"},{"key":"9463_CR13","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","volume":"24","author":"M Maio","year":"2013","unstructured":"Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24:2911\u20135.","journal-title":"Ann Oncol"},{"key":"9463_CR14","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1002\/cncr.28282","volume":"119","author":"JJ Luke","year":"2013","unstructured":"Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119:3687\u201395.","journal-title":"Cancer"},{"key":"9463_CR15","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3109\/0284186X.2013.786839","volume":"52","author":"S Kelderman","year":"2013","unstructured":"Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, et al. Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch working group on immunotherapy of oncology (WIN-O). Acta Oncol. 2013;52:1786\u20138.","journal-title":"Acta Oncol"},{"key":"9463_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma. PLoS One. 2015;10:e0118564.","journal-title":"PLoS One"},{"key":"9463_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2013.09.007","volume":"50","author":"M Del Vecchio","year":"2014","unstructured":"Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, et al. Efficacy and safety of ipilimumab 3mg\/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50:121\u20137.","journal-title":"Eur J Cancer"},{"key":"9463_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","volume":"18","author":"MA Postow","year":"2013","unstructured":"Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013;18:726\u201332.","journal-title":"Oncologist"},{"key":"9463_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1479-5876-12-116","volume":"12","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, et al. Clinical experience with ipilimumab 3 mg\/kg: real-work efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116.","journal-title":"J Transl Med"},{"issue":"suppl 8","key":"9463_CR20","first-page":"13240","volume":"21","author":"C Lebb\u00e9","year":"2010","unstructured":"Lebb\u00e9 C, McDermott DF, Robert C, Lorigan P, Ottensmeier CH, Wolchok J, et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial [abstract]. Ann Oncol. 2010;21(suppl 8):13240.","journal-title":"Ann Oncol"},{"issue":"suppl","key":"9463_CR21","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1200\/jco.2013.31.15_suppl.9063","volume":"31","author":"S Chandra","year":"2013","unstructured":"Chandra S, Madden KM, Kannan R, Pavlick AC. Evaluating the safety of anti-CTLA-4 therapy in elderly patients with unresectable melanoma [abstract]. J Clin Oncol. 2013;31(suppl):9063.","journal-title":"J Clin Oncol"},{"key":"9463_CR22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-014-1400-y","volume":"118","author":"P Queirolo","year":"2014","unstructured":"Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neuro-Oncol. 2014;118:109\u201316.","journal-title":"J Neuro-Oncol"},{"key":"9463_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","volume":"24","author":"LA Emens","year":"2018","unstructured":"Emens LA. Breast Cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:511\u201320.","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"9463_CR24","first-page":"880","volume":"49","author":"FS Hodi","year":"2013","unstructured":"Hodi FS, Topalian SL, Brahmer JR, McDermott DF, Smith DC, Gettinger S, et al. Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. Eur J Cancer. 2013;49(suppl 2):880.","journal-title":"Eur J Cancer"},{"key":"9463_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"key":"9463_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","volume":"35","author":"MA Postow","year":"2015","unstructured":"Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35:76\u201383.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9463_CR27","unstructured":"Prete A, Salvatori R. Hypophysitis. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al. editors. Source Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000\u20132018 Aug 15."},{"key":"9463_CR28","unstructured":"Sarne D. Effects of the Environment, Chemicals and Drugs on Thyroid Function. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000\u20132016 Sep 27."},{"key":"9463_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.","journal-title":"BMC Med"},{"key":"9463_CR30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230\u201340.","journal-title":"Oncologist"},{"key":"9463_CR31","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"9463_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","volume":"85","author":"MN Joshi","year":"2016","unstructured":"Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV. Immune checkpoint inhibitor related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol. 2016;85:331\u20139.","journal-title":"Clin Endocrinol"},{"key":"9463_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195\u2013207.","journal-title":"Nat Rev Endocrinol"},{"key":"9463_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70\u20136.","journal-title":"Cancer Treat Rev"},{"key":"9463_CR35","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691\u20137.","journal-title":"J Clin Oncol"},{"key":"9463_CR36","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","volume":"21","author":"E Gonz\u00e1lez-Rodr\u00edguez","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016;21:804\u201316.","journal-title":"Oncologist"},{"key":"9463_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"9463_CR38","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"9463_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/EJE-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303\u20137.","journal-title":"Eur J Endocrinol"},{"key":"9463_CR40","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","volume":"27","author":"G Borodic","year":"2011","unstructured":"Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011;27:e87\u20138.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"9463_CR41","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"9463_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371\u201381.","journal-title":"Endocr Relat Cancer"},{"key":"9463_CR43","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.2337\/dc15-0889","volume":"38","author":"M Mellati","year":"2015","unstructured":"Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, et al. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes Care. 2015;38:e137\u20138.","journal-title":"Diabetes Care"},{"key":"9463_CR44","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2337\/dc15-0401","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38:e55\u20137.","journal-title":"Diabetes Care"},{"key":"9463_CR45","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","volume":"64","author":"J Martin-Liberal","year":"2015","unstructured":"Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64:765\u20137.","journal-title":"Cancer Immunol Immunother"},{"key":"9463_CR46","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.2337\/dc15-1331","volume":"38","author":"C Gaudy","year":"2015","unstructured":"Gaudy C, Cl\u00e9vy C, Monestier S, Dubois N, Pr\u00e9au Y, Mallet S, et al. Anti-PD1 Pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care. 2015;38:e182\u20133.","journal-title":"Diabetes Care"},{"key":"9463_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70031-7","volume":"1","author":"L Min","year":"2013","unstructured":"Min L, Ibrahim N. Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol. 2013;1:e15.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9463_CR48","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","volume":"40","author":"S Bacanovic","year":"2015","unstructured":"Bacanovic S, Burger IA, Stolzmann P, Hafner J, Huellner MW. Ipilimumab-induced Adrenalitis: a possible pitfall in 18F-FDG-PET\/CT. Clin Nucl Med. 2015;40:e518\u20139.","journal-title":"Clin Nucl Med"},{"key":"9463_CR49","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/jnci\/djr373","volume":"103","author":"OP Hamnvik","year":"2011","unstructured":"Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011;103:1572\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"9463_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"9463_CR51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AV Maker","year":"2006","unstructured":"Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29:455\u201363.","journal-title":"J Immunother"},{"key":"9463_CR52","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681\u20138.","journal-title":"Clin Cancer Res"},{"key":"9463_CR53","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cncr.24951","volume":"116","author":"GY Ku","year":"2010","unstructured":"Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767\u201375.","journal-title":"Cancer"},{"key":"9463_CR54","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"9463_CR55","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","volume":"13","author":"EJ Small","year":"2007","unstructured":"Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810\u20135.","journal-title":"Clin Cancer Res"},{"key":"9463_CR56","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","volume":"26","author":"JS Weber","year":"2008","unstructured":"Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I\/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950\u20136.","journal-title":"J Clin Oncol"},{"key":"9463_CR57","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","volume":"15","author":"SM Ansell","year":"2009","unstructured":"Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15:6446\u201353.","journal-title":"Clin Cancer Res"},{"key":"9463_CR58","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O\u2019Day","year":"2010","unstructured":"O\u2019Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21:1712\u20137.","journal-title":"Ann Oncol"},{"key":"9463_CR59","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","volume":"29","author":"EM Hersh","year":"2011","unstructured":"Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investig New Drugs. 2011;29:489\u201398.","journal-title":"Investig New Drugs"},{"key":"9463_CR60","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828\u201333.","journal-title":"J Immunother"},{"key":"9463_CR61","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","volume":"16","author":"C Ralph","year":"2010","unstructured":"Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16:1662\u201372.","journal-title":"Clin Cancer Res"},{"key":"9463_CR62","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000464285","volume":"6","author":"EH Gan","year":"2017","unstructured":"Gan EH, Mitchell AL, Plummer R, Pearce S, Perros P. Tremelimumab-induced graves hyperthyroidism. Eur Thyroid J. 2017;6:167\u201370.","journal-title":"Eur Thyroid J."},{"key":"9463_CR63","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1210\/jc.2014-4560","volume":"100","author":"S Orlov","year":"2015","unstructured":"Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100:1738\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"9463_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/1346-8138.13028","volume":"43","author":"T Narita","year":"2016","unstructured":"Narita T, Oiso N, Taketomo Y, Okahashi K, Yamauchi K, Sato M, et al. Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2016;43:210\u20134.","journal-title":"J Dermatol"},{"key":"9463_CR65","doi-asserted-by":"crossref","unstructured":"Verma I, Modi A, Tripathi H, Agrawal A. Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung. BMJ Case Rep. 2016;2016.","DOI":"10.1136\/bcr-2015-213692"},{"key":"9463_CR66","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000485742","volume":"7","author":"P Campredon","year":"2018","unstructured":"Campredon P, Imbert P, Mouly C, Grunenwald S, Mazi\u00e8res J, Caron P. Severe inflammatory Ophthalmopathy in a Euthyroid patient during Nivolumab treatment. Eur Thyroid J. 2018;7:84\u20137.","journal-title":"Eur Thyroid J"},{"key":"9463_CR67","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2217\/imt-2017-0174","volume":"10","author":"S Badovinac","year":"2018","unstructured":"Badovinac S, Korsic M, Zarkovic K, Mursic D, Roglic M, Jakopovic M, et al. Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer. Immunotherapy. 2018;10:427\u201331.","journal-title":"Immunotherapy"},{"key":"9463_CR68","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558\u201368.","journal-title":"Lancet Oncol."},{"key":"9463_CR69","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28:583\u20139.","journal-title":"Ann Oncol"},{"key":"9463_CR70","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ijc.28973","volume":"13","author":"A De Remigis","year":"2015","unstructured":"De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, et al. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer. 2015;13:127\u201337.","journal-title":"Int J Cancer"},{"key":"9463_CR71","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1530\/EJE-17-0810","volume":"178","author":"ES Scott","year":"2018","unstructured":"Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018;178:175\u201382.","journal-title":"Eur J Endocrinol"},{"key":"9463_CR72","doi-asserted-by":"crossref","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer 2017;5:95.","DOI":"10.1186\/s40425-017-0300-z"},{"key":"9463_CR73","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"9463_CR74","unstructured":"National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities. (Version 1.2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. [Accessed 30 March 2018]."},{"key":"9463_CR75","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559\u201374.","journal-title":"Ann Oncol"},{"key":"9463_CR76","unstructured":"Merck. Pembrolizumab US full prescribing information. 2014. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. [Accessed April 2017]."},{"key":"9463_CR77","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375\u201391.","journal-title":"Ann Oncol"},{"key":"9463_CR78","unstructured":"Genentech. Atezolizumab US full prescribing information. 2016. http:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf. [Accessed June 2018]."},{"key":"9463_CR79","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0042-119528","volume":"125","author":"M Alhusseini","year":"2017","unstructured":"Alhusseini M, Samantray J. Hypothyroidism in Cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms. Exp Clin Endocrinol Diabetes. 2017;125:267\u20139.","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-018-9463-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-018-9463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-018-9463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:44:26Z","timestamp":1659087866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-018-9463-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12,15]]}},"alternative-id":["9463"],"URL":"https:\/\/doi.org\/10.1007\/s11154-018-9463-2","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"21 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}